Achieve Life Sciences, Inc.
NASDAQAchieve Life Sciences enters the weekend with a striking divergence at its core: short interest has climbed to its highest level in months while the Street's freshest voice just turned bullish. Short interest is the headline story here, and it is genuinely extreme. Bears hold 31.1% of the free float — up 57.9% over the past month and 10.9% on the week alone — reflecting a sustained…
ACHV short interest surges 29.7% in one week to 24.9% of float, highest level in months amid FDA delays for smoking cessation therapy cytisinicline.
Achieve Life Sciences enters the weekend with a striking divergence at its core: short interest has climbed to its highest level in months while the Street's freshest voice just turned bullish. Short interest is the…
ACHV enters the week carrying one of the sharpest short-building episodes in the small-cap biotech space, with bears accelerating positions even as the regulatory story becomes more constructive. Short interest has…
Snapshot as of 21 Sept 2026
Achieve Life Sciences reports Q2 results on July 2 against one of the most charged positioning backdrops in the small-cap biotech universe — a stock up 32% in a month, short sellers at 17.8% of free float, and a borrow…
Three distinct signals are firing on ACHV simultaneously. The borrow market is tightening fast, short interest is elevated and rising, and options traders are piling into calls at a historic rate. The standout signal…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ACHV — free to start on ORTEX.
Sign up for free →Open ACHV on ORTEX